相关实验视频
Updated: Jun 1, 2025

08:40
Methyl-binding DNA capture Sequencing for Patient Tissues
Published on: October 31, 2016
8.6K
瘤DNA甲基化标记与乳腺癌存活率相关:一项复制研究
Elaheh Zarean1, Shuai Li1,2, Ee Ming Wong1
1Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, 246 Clayton Road, Clayton, VIC, 3168, Australia.
Breast cancer research : BCR
|January 17, 2025
概括
DNA甲基化标记物对乳腺癌存活率预测有前途. 这项研究在澳大利亚队列中部分复制了特定DNA甲基化位点和签名与乳腺癌预后之间的关联.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 基因组学就是基因组学.
背景情况:
- 瘤DNA甲基化是一种潜在的乳腺癌生存标志物.
- 之前关于DNA甲基化和生存的发现缺乏一致的复制.
- 研究可复制甲基化标记物对于临床应用至关重要.
研究的目的:
- 复制之前报告的与乳腺癌存活率相关的DNA甲基化标志物.
- 在独立的澳大利亚队列中评估单个CpG站点和多个CpG签名.
- 为了评估DNA甲基化在乳腺癌的预后价值.
主要方法:
- 使用了墨尔本协作队列研究 (MCCS) 澳大利亚乳腺癌样本 (N=425).
- 从TCGA数据中复制了候选DNA甲基化位点 (N=22) 和签名 (N=3).
- 采用考克斯的比例危险回归来分析与生存结果的关联.
主要成果:
- 实现了单个CpG站点 (9/22) 和多CpG签名 (2/3) 的部分复制.
- 复制的关联在乳腺癌特异性存活率方面比整体存活率更强.
- 确定了重要的预后标志物,包括PRAC2 CpG位点和28-CpG签名.
结论:
- DNA甲基化标记物显示出改善乳腺癌预后的潜力.
- 需要进一步的验证研究来证实和扩展这些发现.
- 这项研究支持表观遗传标记在乳腺癌管理中的有用性.
相关概念视频
Epigenetic Regulation
30.9K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
30.9K
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328

